Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management

Netherlands Journal of Medicine

Volumn 69, Issue 1, 2011, Pages 43-49

  Arends, J E ^a   Lambers, F A E ^b   van der Meer, J T M ^c   Schreij, G ^d   Richter, C ^e   Brinkman, K ^f   Hoepelman, A I M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RIJNSTATE HOSPITAL   (Netherlands)

^f Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

Acute hepatitis C; HIV; Peginterferon alfa; Ribavirin; Therapy

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA;

ARTICLE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MONOTHERAPY; OUTCOME ASSESSMENT; SEROCONVERSION; TREATMENT DURATION; TREATMENT INDICATION;

ACUTE DISEASE; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; EVIDENCE-BASED MEDICINE; HEPATITIS C; HIV INFECTIONS; HUMANS; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; TIME FACTORS;

EID: 79952077135     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007;21(8):983-91.
2. Gambotti L, Batisse D, Colin-de-Verdiere N, Aroque-Astagneau E, Desenclos JC, Dominguez S, et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill. 2005;10(5):115-7.
3. Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS. 2009;23(12):F1-F7.
4. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 2007;196(2):230-8.
5. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9(2):82-8.
6. Brook J, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med. 2010;11:1-30.
7. Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat. 2007;14(2):116-21.
8. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452-7.
9. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel MA, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43(5):923-31.
10. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42(3):329-33.
11. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43(2):250-6.
12. Arends JE, Schrover IM, Schaar CG, Mudrikova T, Hoepelman AI. Peginterferon monotherapy for the treatment of acute hepatitis C in HIV-coinfected patients. AIDS. 2008;22(11):1381-2.
13. Vogel M, Rockstroh JK. Treatment of acute hepatitis C in HIV infection. J Antimicrob Chemother. 2010;65(1):4-9.
14. Arends JE, Mudrikova T, Wensing AMJ, Wind CM, van Baarle D, Hoepelman AIM. High Percentage Of Non-response With Peginterferon-alfa-2a Monotherapy For The Treatment Of Acute Hepatitis C In HIV Infected Patients. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009;abstract no. 2458.
15. De Rosa FG, Mollaretti O, Audagnotto S, De BT, Cariti G, Marucco DM, et al. Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients. Clin Infect Dis. 2009;48(11):1636-7.
16. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20(8):1157-61.
17. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40(1):41-6.
18. Lambers F, van den Berk G, van der Meer J, Spijkerman I, Molenkamp R, Coutinho R, et al. Treatment Outcome of Acute Hepatitis C Virus Infection in HIV-infected MSM: the effect of treatment length. 17th Conference on Retroviruses and Opportunistic Infections 2010;abstract no. 641.
19. Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS. 2009;23(16):2079-89.
20. Schulze Zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, et al. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis. 2009;49(3):466-72.
21. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS. 2006;20(2):233-40.
22. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009;48(5):650-8.
23. Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol. 2010;22(2):157-66.
24. Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat. 2005;12(2):207-11.
25. Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006;11(8):1097-101.
26. Arends JE, Mudrikova T, Wensing AMJ, Wind CM, van Baarle D, Hoepelman AIM. High percentage of non-response with peginterferon-alfa-2a monotherapy for the treatment of acute hepatitis C in HIV infected patients. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009;abstracht no. 2458.
27. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20(8):1157-61.
28. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40(1):41-6.
29. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41(1):31-6.
30. Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol. 2010;22(2):157-66.
31. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009;48(5):650-8.
32. Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS. 2009;23(16):2079-89.
33. Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat. 2005;12(2):207-11.
34. Schulze Zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, et al. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis. 2009;49(3):466-72.
35. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS. 2006;20(2):233-40.
36. Danta M, Turner JM, Johnstone R, Lascar RM, Johnson MA, Dusheiko GM, et al. Use of pegylated interferon-alpha (peg-IFN) with or without ribavirin in the treatment of acute HCV in HIV-positive individuals. HIV Med. 2005;6:14-55.
37. Chamie G, Bonacini M, Bangsberg DR, Stapleton JT, Hall C, Overton ET, et al. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis. 2007;44(4):577-83.
38. Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS. 2009;23(1):89-93.
39. Arends JE, Mudrikova T, Wensing AMJ, Wind CM, van Baarle D, Hoepelman AIM. High percentage of non-response with peginterferon-alfa-2a monotherapyfor the treatment of acute hepatitis C in HIV infected patients. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009; abstract no. 2458.
40. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS. 2006;20(2):233-40.
41. De Rosa FG, Mollaretti O, Audagnotto S, De BT, Cariti G, Marucco DM, et al. Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients. Clin Infect Dis. 2009;48(11):1636-7.
42. Schulze Zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, et al. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis. 2009;49(3):466-72.
43. Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat. 2005;12(2):207-11.
44. Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol. 2010;22(2):157-66.
45. Arends JE, van Assen S, Stek C, Wensing AMJ, Fransen JH, Schellens IM, et al. High rate of non-response and relapse in HIV infected patients treated with peginterferon-alfa mono-therapy for acute hepatitis C. 20th European Congress of Clinical Microbiology and Infectious Diseases 2010; abstract no. 1146.
46. Arends JE, Mudrikova T, Wensing AMJ, Wind CM, van Baarle D, Hoepelman AIM. High percentage of non-response with peginterferon-alfa-2a monotherapy for the treatment of acute hepatitis C in HIV infected patients. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009;abstract no. 2458.
47. Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol. 2010;22(2):157-66.
48. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS. 2006;20(2):233-40.
49. De Rosa FG, Mollaretti O, Audagnotto S, De BT, Cariti G, Marucco DM, et al. Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients. Clin Infect Dis. 2009;48(11):1636-7.
50. Schulze Zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, et al. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis. 2009;49(3):466-72.
51. Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat. 2005;12(2):207-11.
52. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009;48(5):650-8.
53. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20(8):1157-61.
54. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40(1):41-6.
55. Matthews GV, Grebely J, Hellard M, Yeung B, Marks P, Rawlinson W, et al. Differences in early virological decline in individuals treated within the Australian trial in acute HCV suggest a potential benefit for the use of ribavirin. 45th Annual Meeting of the European Association for the Study of the Liver 2010;April 14 - 18, 2010, Vienna, Austria.
56. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125(1):80-8.
57. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20(8):1157-61.
58. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40(1):41-6.
59. Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS. 2009;23(16):2079-89.
60. Fierer DS, Fishman S, Uriel AJ, Carriero DC, Factor S, Mullen MP, et al. Characterization of an Outbreak of Acute HCV Infection in HIV-infected Men in New York City. 16th Conference on Retroviruses and Opportunistic Infections 2009;abstract no. 802.
61. Vogel M, Page E, Matthews GV, Guiguet M, Dominguez S, Dore GJ, et al. Use of week 4 HCV RNA after acute HCV infection to predict chronic HCV infection. 17th Conference on Retroviruses and Opportunistic Infections 2010;February 16-19, San Francisco, United States.
62. McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009;49(7):1051-60.
63. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009;48(5):650-8.
64. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004;39(5):1213-9.
65. Vogel M, Rockstroh JK. Treatment of acute hepatitis C in HIV infection. J Antimicrob Chemother. 2010;65(1):4-9.